<DOC>
	<DOCNO>NCT00340314</DOCNO>
	<brief_summary>Background : Circumferential pulmonary vein ablation ( CPVA ) safely effectively perform treat paroxysmal atrial fibrillation ( PAF ) ; however , safety efficacy , compare antiarrhythmic drug therapy ( ADT ) , never formally assess randomize control trial . The Purpose study evaluate CPVA versus ADT patient PAF randomize control trial .</brief_summary>
	<brief_title>A Trial Circumferential Pulmonary Vein Ablation ( CPVA ) Versus Antiarrhythmic Drug Therapy Paroxysmal Atrial Fibrillation ( AF )</brief_title>
	<detailed_description>Antiarrhythmic drug therapy ( ADT ) currently consider first-line therapy patient paroxysmal atrial fibrillation ( AF ) .1 However antiarrhythmic drug frequently ineffective serious potential adverse effect , thus often offset advantage offer maintenance sinus rhythm ( SR ) .2,3 Data laboratory suggest pulmonary vein ablation technique may curative alternative AF , obviate need ADT and/or anticoagulation many patients.4-8 However , preliminary frequently non-randomized data exist evidence-based evaluation catheter ablation compare conventional antiarrhythmic drug therapyADT.4,8 Thus , conduct control randomize trial ( Ablation Paroxysmal Atrial Fibrillation [ APAF ] trial ) determine long-term efficacy circumferential pulmonary vein ablation ( CPVA ) patient paroxysmal AF compare ADT flecainide , sotalol amiodarone . Methods : One hundred ninety-eight patient ( age , 56±10 year ) PAF ( duration , 6±5 year , mean AF episodes 3.4/month ) , randomize CPVA ADT flecainide , sotalol amiodarone . Ablation randomly perform use standard irrigate tip catheter CARTO NavX non fluoroscopic 3D system guidance . Cardiac rhythm assess daily transtelephonic transmission 12 48 month follow-up . Crossovers CPVA allow 3 month ADT . Results : By Kaplan-Meier analysis , 86 % patient CPVA group 22 % ADT group free recurrent atrial tachyarrhythmias ( [ AT ] P &lt; 0.001 ) ; repeat ablation perform 9 % patient CPVA group recurrent AF ( 6 % ) atrial tachycardia ( 3 % ) . At 1 year , 93 % 35 % CPVA ADT group AT-free 4 year 72.7 % patient assign RFA 12.1 % assign AADs reach endpoint ( p &lt; 0.001 ) .Lower leave ejection fraction , arterial hypertension age independently predict AF recurrence ADT group . CPVA associate significant decrease leave atrial diameter ( 15±10 % , P &lt; 0.01 ) few number cardiovascular hospitalization ( p &lt; 0.01 ) . Ablation irrigate tip catheter effective ( P=0.03 ) either CARTO NavX system ( P=0.08 ) . One transient ischemic attack one pericardial effusion occur CPVA group ; side effect ADT report 23 patients.During 4-year follow-up , 87 initially AADs patient require cross RFA steeper rate 1 year ( 42 patient ) 19 progressed persistent AF switching . Considering repeat ablation crossover , overall success rate 90 % RFA group 80 % AAD group ( p=0.0023 , log-rank test ) . New leave AT develop 9 patient require map ablation 7 patient . Quality life high RFA group AAD group subscale score ( p &lt; 0.001 ) Conclusions : Compared ADT , CPVA safely effectively cure PAF many patient one-year follow-up benefit extend 4 year .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Anti-Arrhythmia Agents</mesh_term>
	<criteria>1 . Age 1870 year 2 . History symptomatic paroxysmal AF last 6 month . Paroxysms AF intend recurrent selfterminating episode last less 7 day occur 2 time every month . 1 . Pregnancy 2 . NYHA functional class III IV 3 . Left atrial size &gt; 65 mm 4 . Left ventricular ( LV ) ejection fraction &lt; 35 % 5 . Contraindication anticoagulation warfarin 6 . History myocardial infarction within six month procedure 7 . Prior catheter surgical ablation attempt AF 8 . Inability unwillingness provide write informed consent 9 . Life expectancy less 1 year 10 . Significant comorbid condition : cancer ( cure ) , end stage renal disease ( creatinine clearance &lt; 20 mL/h ) , severe chronic obstructive lung disease , cirrhosis , etc ) 11 . Anticipated cardiac surgery congenital , valvular , aortic coronary heart disease . 12 . Presence leave atrial thrombus . 13 . Prior antiarrhythmic drug therapy amiodarone , sotalol flecainide optimal dos ( target 200 mg , 240 mg , 200 mg daily respectively 14 . AF burden &lt; 2 episodes/month 15 . WPW 16 . Expected survival &lt; 1 year 17 . Contraindications antiarrhythmic therapy include flecainide , sotalol amiodarone list : LV hypertrophy ( LV mass index &gt; 125g/m2 ) thyroid dysfunction ( hyperthyroidism uncontrolled hypothyroidism thyroid cancer ) liver dysfunction ( ALT AST &gt; 2x reference value ) Interstitial lung disease DLCO &lt; 70 % predict severe asthma . QT interval exceed 400 msec Symptomatic sinus node atrioventricular node dysfunction unless pacemaker implant Evidence stressinduced myocardial ischemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>symptomatic</keyword>
	<keyword>paroxysmal</keyword>
	<keyword>atrial fibrillation</keyword>
</DOC>